Serum thyroid hormone antibodies are frequent in patients with polyglandular autoimmune syndrome type 3, particularly in those who require thyroxine treatment [PDF]
, 2017 Polyglandular autoimmune syndrome (PAS) type 3 consists of autoimmune thyroid disease (AITD) coexisting with ≥1 non-thyroidal autoimmune disease (NTAID) other than Addison’s disease and hypoparathyroidism. We evaluated the prevalence and repertoire of
Benvenga, Salvatore +8 more
core +1 more source
Subcutaneous immunoglobulin replacement therapy
Current Opinion in Allergy & Clinical Immunology, 2013 Rapid subcutaneous immunoglobulin (SCIg) infusions have been used as an important method of delivering replacement immunoglobulin (Ig) to patients with primary immune deficiencies (PIDs) in Europe over the last 25 years. This review provides a comprehensive interpretation of the literature relating to the administration of SCIg and the services that ...
Chapel, H, Gardulf, A
openaire +2 more sources
Immunoglobulin replacement therapy targeting the BCR in chronic lymphocytic leukemia. [PDF]
EBioMedicine, 2018 Ferrer G.
europepmc +4 more sources
Acute reduction in secretory immunoglobulin A following smoking cessation [PDF]
, 2004 Smokers report an increase in upper respiratory infections in the early phase of stopping smoking. One possible cause is a depletion in secretory immunoglobulin A (S-IgA) which has been observed in one study.
Clow, A +6 more
core +1 more source
Immunoglobulin Replacement Therapy for Primary Immunodeficiencies
Immunotherapy, 2014 Exogenous antibody therapy to protect patients against infections and toxins is over 100 years old, yet progress continues to be made in the manufacture, administration and application of this type of immunotherapy, known as therapeutic human immunoglobulin. For the majority of patients with primary immunodeficiencies, immunoglobulin replacement is the
Peter, J, Chapel, H
openaire +2 more sources
Intravenous immunoglobulins in immunodeficiencies: more than mere replacement therapy [PDF]
Clinical and Experimental Immunology, 2011 Summary Intravenous immunoglobulin (IVIG) is a therapeutic compound prepared from pools of plasma obtained from several thousand healthy blood donors. For more than 20 years, IVIG has been used in the treatment of a wide range of primary and secondary immunodeficiencies. IVIG now represents a standard therapeutic option for most antibody
S V, Kaveri +4 more
openaire +2 more sources
Mechanisms of action of Ig preparations: immunomodulatory and anti-inflammatory effects
Frontiers in Immunology, 2015 Primary immunodeficiency (PIDs) disorders that predispose patients to recurrent infections require immunoglobulin (Ig) replacement therapy. Ig replacement therapy has been defined as beneficial, although the optimal IgG trough level to be maintained over
Andrea eMatucci +2 more
doaj +1 more source
PLoS ONE, 2014 BackgroundRegular intravenous immunoglobulin treatment is used to replace antibody deficiency in primary immunodeficiency diseases; however the therapeutic effect seems to be related not only to antibody replacement but also to an active role in the ...
Marzia Dolcino +9 more
doaj +1 more source
Pulmonary Manifestations of Primary Humoral Deficiencies
Canadian Respiratory Journal, 2022 Primary immunodeficiencies are a group of conditions characterized by developmental or functional alterations in the immune system caused by hereditary genetic defects.
Ana Casal +7 more
doaj +1 more source
Immunodeficiency in DiGeorge Syndrome and Options for Treating Cases with Complete Athymia. [PDF]
, 2013 The commonest association of thymic stromal deficiency resulting in T-cell immunodeficiency is the DiGeorge syndrome (DGS). This results from abnormal development of the third and fourth pharyngeal arches and is most commonly associated with a ...
Davies, EG
core +2 more sources